STSA - Analysts bails on Satsuma Pharma after underwhelming STS101 data in migrane September, 11 2020 09:00 AM Satsuma Pharmaceuticals Inc. Satsuma Pharmaceuticals (NASDAQ:STSA) slips 4% premarket after downgrades by Credit Suisse, Mizuho and Leeirk.More news on: Satsuma Pharmaceuticals, Inc., Healthcare stocks news, Read more ...